Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin beta-1-binding protein 2 (ITGB1BP2), also known as Melusin and CHORDC3, is a co-chaperone protein characterized by two cysteine and histidine-rich (CHORD) domains and multiple protein–protein interaction motifs, including PXXP and YXXI/P sequences[4]. It primarily interacts with the beta-1 integrin subunit in a cation-dependent manner, excluding calcium[6]. ITGB1BP2 is expressed in cardiac and skeletal muscle and participates in muscle cell maturation, organization, and possibly mechanotransduction associated with integrin signaling[5][6]. Functional data in mouse and human indicate involvement in muscle development, cell differentiation, and adaptation to mechanical stress[3][5]. While not a canonical drug target like a receptor or enzyme, its role in muscle and cardiovascular biology suggests indirect relevance in disease mechanisms, especially myocardial adaptation to stress and muscle plasticity[3][5]. Currently, there are no known drugs or clinical biomarkers that directly target ITGB1BP2, nor reported safety concerns specific to its modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin beta-1-binding protein 2 (ITGB1BP2).